Treatment of hereditary angioedema: When the goal is having a normal life

Affiliations

¹ Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. Electronic address: karla@fmrp.usp.br.
² Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

Editorial

Luisa Karla Arruda et al. J Allergy Clin Immunol. 2021 Jul.

. 2021 Jul;148(1):80-82.

doi: 10.1016/j.jaci.2021.05.023. Epub 2021 May 28.

¹ Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. Electronic address: karla@fmrp.usp.br.
² Department of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.

No abstract available

Keywords: Angioedema; berotralstat; bradykinin; hereditary angioedema; kallikrein; kallikrein inhibitor.

Comment on

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Zuraw B, Lumry WR, Johnston DT, Aygören-Pürsün E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlíková J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA. Zuraw B, et al. J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9. doi: 10.1016/j.jaci.2020.10.015. Epub 2020 Oct 21. J Allergy Clin Immunol. 2021. PMID: 33098856 Clinical Trial.